NTLA Intellia Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1652130 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.1%
TTM net income YoY4.4%
TTM EPS YoY21.2%
Revenue 3-yr CAGR77.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-821.2%
Net margin-805.7%
FCF margin-677.1%
EBITDA margin-805.0%
Returns
ROE-62.6%
ROA-46.6%
ROIC (approx.)-63.2%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.12x
Current ratio6.31x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $67.67M | $57.88M |
| R&D expense | $388.86M | $466.31M |
| SG&A expense | $119.80M | $125.83M |
| Operating income | -$440.99M | -$534.26M |
| Income tax | $0 | — |
| Net income | -$412.69M | -$519.02M |
| EBITDA | -$431.22M | -$523.98M |
| EPS (basic) | -3.81 | -5.25 |
| EPS (diluted) | -3.81 | -5.25 |
| Weighted avg. shares (diluted) | 108.38M | 98.85M |
| Balance sheet | ||
| Cash & equivalents | $155.46M | $189.18M |
| Short-term investments | $294.42M | $412.33M |
| Receivables | $9.47M | $8.52M |
| Current assets | $527.71M | $639.86M |
| PP&E, net | $17.67M | $27.38M |
| Total assets | $842.13M | $1.19B |
| Current liabilities | $103.88M | $110.85M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $170.73M | $319.06M |
| Shareholders' equity | $671.39M | $871.96M |
| Net debt | -$155.46M | — |
| Shares outstanding | 116.32M | 102.03M |
| Cash flow statement | ||
| Operating cash flow | -$394.74M | -$348.88M |
| Capital expenditure | $1.13M | $5.78M |
| Free cash flow | -$395.87M | -$354.66M |
| Investing cash flow | $228.03M | $125.57M |
| Financing cash flow | $131.49M | $185.75M |
| Depreciation & amortization | $9.77M | $10.29M |
| Stock-based compensation | $80.22M | $154.27M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.